IQ-AI, the healthcare technology and software holding company formerly known as Flying Brands, announced it has filed a patent for MR imaging that does not use gadolinium-based contrast agents (GBCAs). According to the company, the product was designed using deep learning techniques.
“We are delighted to announce the filing of this patent,” David Smith, CEO of IQ-AI’s operating subsidiaries, said in a prepared statement. “We believe the potential exists to develop, for the first time, a contrast agent-free imaging technology that should generate output comparable to traditional contrast-based imaging, offering significant savings to global healthcare systems. We now intend to develop the technology and conduct the clinical work necessary to prepare for worldwide regulatory submissions.”
The software was developed by Elm Grove, Wisconsin-based Imaging Biometrics, which was then acquired by IQ-AI in May 2018.
For more Radiology Business coverage of GBCAs, including more recent controversies surrounding potential gadolinium retention in the brain, click here and here.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.